Diagnosis and management of polycystic liver disease (Q38072284)

28 August 2017

1 reference

title

Diagnosis and management of polycystic liver disease (English)

1 reference

28 August 2017

Tom J G Gevers

1

1 reference

28 August 2017

Joost P H Drenth

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

8 January 2013

1 reference

Nature Reviews Gastroenterology & Hepatology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

101-108

1 reference

Medical and surgical treatment options for polycystic liver disease1

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Mutations in SEC63 cause autosomal dominant polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Polycystic disease of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Autosomal dominant polycystic kidney disease: the last 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Role of primary cilia in the pathogenesis of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Polycystic liver disease is a disorder of cotranslational protein processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Development of the bile ducts: essentials for the clinical hepatologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Congenital fibrocystic liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Polycystic Liver Diseases: Congenital Disorders of Cholangiocyte Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Polycystins, focal adhesions and extracellular matrix interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Altered store operated calcium entry increases cyclic 3′,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Sirolimus reduces polycystic liver volume in ADPKD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Somatostatin analogues for treatment of polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Cystic disease in women: clinical characteristics and medical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Clinical profile of autosomal dominant polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys. a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Positron-emission computed tomography in cyst infection diagnosis in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Natural history of autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Unified criteria for ultrasonographic diagnosis of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Isolated polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Screening for Intracranial Aneurysm in 355 Patients With Autosomal-Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Low prevalence of cardiac valve abnormalities in patients with autosomal dominant polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Prevalence of cysts in seminal tract and abnormal semen parameters in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Single-session alcohol sclerotherapy in symptomatic benign hepatic cysts performed with a time of exposure to alcohol of 10 min: initial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Surgical management of polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Tailoring the management of nonparasitic liver cysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Liver transplantation for polycystic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

ERCP for the treatment of bile leak after partial hepatectomy and fenestration for symptomatic polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Systematic review: the pathophysiology and management of polycystic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Liver transplantation: the current situation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Somatostatin and its receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

The long‐term outcome of patients with polycystic liver disease treated with lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

It’s not all in the cilium, but on the road to it: Genetic interaction network in polycystic kidney and liver diseases and how trafficking and quality control matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Extensive mutational analysis of PRKCSH and SEC63 broadens the spectrum of polycystic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Volume progression in polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Adult polycystic liver disease: is fenestration the most adequate operation for long-term management?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Treatment of polycystic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Model for end-stage liver disease (MELD) exception for polycystic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the s

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Intravascular embolization therapy in a patient with an enlarged polycystic liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Angiogenesis in autosomal-dominant polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRGASTRO.2012.254

Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum

31 March 2020

1 reference

12 December 2020

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

1 reference

12 December 2020

Somatic second-hit mutations leads to polycystic liver diseases

1 reference

12 December 2020

Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease

1 reference

12 December 2020

Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil

1 reference

12 December 2020

Imaging of infectious diseases using [18F] fluorodeoxyglucose PET.

1 reference

12 December 2020

10.1038/NRGASTRO.2012.254

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1018266999

0 references

1 reference